analysis.9 Marker characterisation and selection for genotypic diagnosis were investigated in a previously described 36 member nonAshkenazi Jewish family panel. 9 The reliability of indirect genotypic diagno- bp, respectively. Allele frequencies and linkage disequilibrium (Pexcess) were estimated as described previously9 from the first family panel.
Results

SELECTION OF THE BEST MICROSATELLITE MARKER SET FOR GENOTYPIC DIAGNOSIS
We used our previous data for fine MEF localisation9 and also examined four microsatellite markers recently located in chromosome 16pl3.3, that is, D16S134 and D16S3082, which cosegregated with D1 6S3070 in the CEPH family panel, and D1 6S468 and D16S2622 (GDB). It became clear that all markers were not of equal interest for genotypic diagnosis of the disease (table 1) . At the telomeric end of MEF, a cluster of three markers (D16S291, D16S283, and D16S94) was shown to be located quite far (3-4 cM) from the mutation.'3 We selected D16S283, since D16S291 showed no alleles in significant linkage disequilibrium with the disease and D1 6S94 was not very informative. Although we found that marker D 16S3124 had two alleles in linkage disequilibrium, it was still selected for diagnosis because no other marker was located within the 1-2 cM DNA segment telomeric to MEF.
We had already found two markers (D 16S3070 and D 16S3275) that never recombined with the gene throughout 310 meioses studied. As expected, we discovered no crossover between MEF and D 16S3082. Its position relative to D16S3070 and D16S3275 therefore could not be determined on the genetic map. Allele 3 of D16S3082 displayed the strongest linkage disequilibrium (Pexcess=0.8) with the disease (table 1). The core 3-3-9 (or 3-3-18) haplotype (D16S3070, D16S3082, and D16S3275, respectively) was present in 70% of mutated chromosomes, whereas it was never found in non-mutated chromosomes in our ini- All members of one branch of the family were affected: the two parents (subjects 25 and 82) linked by two inbreeding loops and their three children (subjects 83, 84, and 85). Examination of their haplotypes showed that subject 25 had inherited two identical mutated chromosomes, and one copy was also transmitted to his wife, subject 82 (fig 1) . This haplotype was again duplicated in two of their children (Nos 83 and 85). The FMF mutation was easily traced in this pedigree, even when restricting the analysis to the panel of seven markers described above. Subject 78, who presented "late onset FMF" had only one known FMF chromosome. Since three of his sibs (subjects 77, 79, and 81) were haploidentical without any FMF symptoms after the age of 50 years, the present results strongly suggest that subject 78 was precipitately diagnosed, owing to the high number of FMF cases in this family.
All FMF bearing chromosomes in family 75 were of ancestral origin, at least at the three core loci (D16S3070, D16S3082, D16S3275), except for one carried by subject 9 and her daughter No 16 (alleles 5-11-5 respectively at the three core markers). Subject 5, who was symptom free, showed the same genotype as her affected sister (No 4). She is probably concerned by the known low, sometimes age dependent, penetrance of the disease in affected females,'4 since she was 25 when she was genotyped, and her affected mother (No 1) and sister (No 22) only showed symptoms of the disease after the age of 30 years.
Family 21 (fig 2) illustrates most situations that can be encountered in genetic counselling. Almost all members of this family were of Algerian origin. Subject 31 had the full range of FMF symptoms (fever, abdominal and joint pain) at the age of 6 years. Although subjects 11 and 12 also displayed typical FMF, the older sister (No 11) had had an appendectomy before FMF was diagnosed, because of acute abdominal attacks during adolescence. Her major symptoms then switched to episodes of shortness of breath, probably owing to pleuritis. Subject 28 endured the most severe form of FMF in the pedigree (fever reaching 41 C, extreme asthenia, peritonitis, pleuritis, and orchitis). He had the first attacks at the age of 10 months and also underwent unnecessary surgery. The diagnosis was delayed until the age of 3 years. Subject 29 suffered from recurrent episodes of joint pain associated with fever (38-39°C) and had sterile meningitis at the age of 4 .~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~r (table 2) . Indeed, 63% of Jewish patients of North African origin had both chromosomes of the ancestral type (3-3-9 and 3-3-9 or 3-3-9 and 3-3-18) and this rate reached 73% when one mutation was allowed at the three core loci, provided that our two proposed bracketing markers also exhibed ancestral alleles in linkage disequilibrium. Twenty-two percent of patients carried one ancestral haplotype, and as few as 5% had no ancestral mutated chromosome. Even more specific, allele 18 of D16S3275 was only noted in FMF mutated chromosomes9 (present study). Among the 101 independent normal chromosomes studied in our latter family panel, only one apparently non-mutated chromosome exhibited the 3-3-9 haplotype (subject 1, family 14). Thus, diagnosis based on detection of the homozygous status for the 3-3-9 haplotype in the non-Ashkenazi Jewish patients resulted in a very low risk of error (2.10'), the chance occurrence of each ancestral allele being 0.2, 0.11, and 0.2 at D16S3070, D16S3082, and D16S3275, respectively, in this population (table 1) .
We then retrospectively compared the potential benefits of each linkage approach in our FMF affected population. The initial clinical diagnoses per patient were plotted against the corresponding genotypic statuses established in the present study (table 2) . From a total of 84 clinically diagnosed patients who could be genotyped, 76 (90%) exhibited an informative genotype with either or both linkage approaches. Genotypes were found to be consistent with clinical diagnosis in all patients except subject 78, family 75 and subject 30, family 21, who exhibited one mutated ancestral chromosome and one apparently non-pathogenic chromosome. Since the three markers that never recombine with the disease gene were informative in these two patients, FMF may be genotypically refuted with less than 1% risk, which a postiori might explain the misdiagnosis described earlier. It is noteworthy that the disequilibrium linkage approach alone was (28) 20 (4, 6) 23 (1) 22 (2, 5) 55 (5) 55 (11,12) 57 (2) 57 (4, 5) 65* (34) 65 (43) 69 (6) 60 (1, 4) 60* (8, 9, 11) 60* (12) 69 (8) 65 ( (4) 75 (5) 73% 75 (6) 75 (13, 14) 75* (25) 75* (18,19) 75 (82) 75 (89) 85 (3, 5, 7) 78 (2) 81 (2,3) 78 (7) 93 (15) 93 (3, 5, 7) 94 (3) 105 (5) 122 (7) 106 (3) 108 (1) 119 (10) 108 (4) 83 (1) 67 (3) 68 (3) 73 (5) 75 (16) 91 (3) 91 (4) Using classical linkage analysis with the proposed highly informative set of markers, the parental origin of the two chromosomes could be confirmed in 100% of cases in the first family panel and in 99% of cases in the second (in subject 71, family 21, one more telomeric marker was needed). This approach is restricted to cases where DNA from FMF affected relatives is available from both parental sides. However, we obtained more accurate indirect diagnoses through the strong founder effect noted in non-Ashkenazi Jewish families. With 73% of FMF patients exhibiting homozygosity for the ancestral haplotype in this population, the risk of error was much lower with the linkage disequilibrium approach, which is especially appropriate for isolated cases. In practice, we propose the following two step strategy for genotypic FMF tests: (1) search for the ancestral haplotype in the putative FMF chromosomes, then (2) familial studies if fewer than two ancestral haplotypes are found. The clear limit of the disequilibrium linkage approach is that, in an isolated person in whom FMF is suspected, the lack of 3-3-9 homozygosity cannot refute the diagnosis.
Besides the advantages of genotyping for FMF diagnosis in people with symptoms, the present report shows that the proposed test will also be of use for care management. Screening heterozygous couples in families at risk, such as subjects 14 and 25 in family 21, will allow early detection of children who have inherited two mutated alleles. Presymptomatic diagnosis can now be expected, since we could predict the heterozygous status of subject 9 (family 21) before knowing that she had one affected relative, although the origin of her ancestral haplotype has not yet been definitely proven, as no DNA is available from her dead cousin. We were also able, through detection of ancestral core alleles, successfully to confirm the diagnosis for an 
